Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

被引：20

作者：

Chang, Anne Lynn S. ^{[1
]}

Lewis, Karl D. ^{[2
]}

Arron, Sarah T. ^{[3
]}

Migden, Michael R. ^{[4
]}

Solomon, James A. ^{[5
,6
,7
]}

Yoo, Simon ^{[8
]}

Day, Bann-Mo ^{[9
]}

McKenna, Edward F. ^{[9
]}

Sekulic, Aleksandar ^{[10
]}

机构：

[1] Stanford Univ, Redwood City, CA USA

[2] Univ Colorado, Aurora, CO USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Ameriderm Res, Ormond Beach, FL USA

[6] Univ Cent Florida, Orlando, FL 32816 USA

[7] Univ Illinois, Urbana, IL 61801 USA

[8] Northwestern Univ, Chicago, IL 60611 USA

[9] Genentech Inc, San Francisco, CA 94080 USA

[10] Mayo Clin, Scottsdale, AZ USA

来源：

ONCOTARGET | 2016年 / 7卷 / 46期

关键词：

basal cell carcinoma; vismodegib; age; hedgehog pathway inhibitor; locally advanced basal cell carcinoma;

D O I：

10.18632/oncotarget.12660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because many patients with unresectable basal cell carcinoma (BCC) are aged >= 65 years, this study explores the efficacy and safety of vismodegib in these patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) in the ERIVANCE BCC trial and the expanded access study (EAS). We compared patients aged >= 65 years to patients aged <65 years taking vismodegib 150 mg/day, using descriptive statistics for response and safety. Patients aged >= 65 years (laBCC/mBCC) were enrolled in ERIVANCE BCC (33/14) and EAS (27/26). Investigator-assessed best overall response rate in patients >= 65 and <65 years was 46.7%/35.7% and 72.7%/52.6% (laBCC/mBCC), respectively, in ERIVANCE BCC and 45.8%/33.3% and 46.9%/28.6%, respectively, in EAS. These differences were not clinically meaningful. Safety was similar in both groups, although those aged >= 65 years had a higher percentage of grade 3-5 adverse events than those aged <65 years. Vismodegib demonstrated similar clinical activity and adverse events regardless of age.

引用

页码：76118 / 76124

页数：7

共 10 条

[1] Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib [J].